City Briefs: Tissue Regenix; Getech

Medical devices company Tissue Regenix expects to report a 19% increase in its half-year revenues as it extends its growth streak to three years.

The York-based business generated sales of $14.1m in the six months to June.

The AIM-listed business told shareholders it is “the sixth consecutive reporting period of growth for the group” and is confident it is on track to meet its expectations for the full year.

Tissue Regenix’s chief executive Daniel Lee said: “Our H1 2023 results are indicative of the continued above-market growth in our key businesses and our ability to deliver on the board’s expectations for our financial performance.”

*****

Earth sciences group Getech has signed three deals totalling £0.8m for its data platform, Globe.

One contract is a new, three-year Globe subscription for an Asian oil and gas company, while the other two contracts are one-year extensions.

£381,000 of revenue will be recognised in the current financial year.

AIM-listed Getech said the contracts “represent significant additions to the group’s existing orderbook”, which now stands at £4.2m.

Getech’s executive chairman Richard Bennett said: “The company continues to service and expand its long-standing oil and gas client base as these contracts show, enabling our clients to search for new resources far more efficiently and by doing so, significantly reduce their exploration costs.”